Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone
✍ Scribed by Vogt, M. (author);Derendorf, H. (author);Krämer, J. (author);Junginger, H. E. (author);Midha, K. K. (author);Shah, V. P. (author);Stavchansky, S. (author);Dressman, J. B. (author);Barends, D. M. (author)
- Publisher
- John Wiley and Sons Inc.
- Year
- 2007
- Tongue
- English
- Weight
- 143 KB
- Volume
- 96
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing rifampicin as the only Active Pharmaceutical Ingredient (API) are reviewed. Rifampicin's so
Literature data are reviewed on the properties of ibuprofen related to the biopharmaceutics classification system (BCS). Ibuprofen was assessed to be a BCS class II drug. Differences in composition and/or manufacturing procedures were reported to have an effect on the rate, but not the extent of abs
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical ingredient (API) are reviewed. Isoniazid's solubility and permeability character
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisone are reviewed. Due to insufficient data prednisone cannot be definitively classified according to the current Biop